Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 GeneticVariation disease BEFREE Degradation of MCL-1 by bufalin reverses acquired resistance to osimertinib in EGFR-mutant lung cancer. 31301315 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE Using the Mcl-1-binding PH domain of Akt as a docking site, we identified a novel small molecule, PH-687, that directly targets the PH domain and disrupts Mcl-1/Akt binding, leading to suppression of Akt activity and growth inhibition of lung cancer <i>in vitro</i> and <i>in vivo</i>. 31662324 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE In this study, we characterize the MCL-1 inhibitor maritoclax alone or in combination with a BCL-2/xL inhibitor in a panel of lung cancer cell lines. 31150457 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 PosttranslationalModification disease BEFREE Thus, nicotine-induced cell survival and chemoresistance may occur in a mechanism by stimulating Mcl-1 phosphorylation and its interaction with Bak, which may contribute to improving the efficacy of chemotherapy in the treatment of human lung cancer. 30741422 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE The CUL5 ubiquitin ligase complex mediates resistance to CDK9 and MCL1 inhibitors in lung cancer cells. 31294695 2019
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE Mechanistically, DTCs undergo a protein biosynthesis enrichment resulting in increased mTORC1-mediated mRNA translation of MCL-1, revealing a novel mechanism in which lung cancer cells adapt to short-term pressures of apoptosis-inducing kinase inhibitors. 30087143 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE Imperatorin Targets MCL-1 to Sensitize CD133+ Lung Cancer Cells to γδ-T Cell-Mediated Cytotoxicity. 30138935 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer. 29484127 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE Caenepeel and colleagues and Ramsey and colleagues have developed two novel, potent, and selective MCL1 inhibitors that are effective against many hematologic malignancies, and Nangia and colleagues describe how one of these inhibitors can be successfully combined with BCL-xL and MEK inhibition to treat KRAS-mutated lung cancer.<i>See related article by Ramsey et al., p. 1566</i>.<i>See related article by Caenepeel et al., p. 1582</i>.<i>See related article by Nangia et al., p. 1598</i>. 30510014 2018
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE Therefore, our study suggests that the protein stability of Mcl-1 is governed by FBXO4, which plays an important role in cell survival and chemotherapy for lung cancer. 28776569 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE These studies suggest that simultaneous blocking of ATM/Mcl-1 molcules or downstream Erk signaling may recover the cisplatin-resistance of lung cancer. 28686074 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE Lung cancer models stably expressing BCL-xL or MCL-1 were irradiated to study cell death, clonogenic survival, and DNA repair kinetics in vitro, and growth suppression of established tumors in vivo. 28432456 2017
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE In the present study, we acidized the medium with 2-(N-morpholino)-ethanesulfonic acid (MES monohydrate) to mimic the acidic tumor microenvironment and observed the effects of acidification on lung cancer cell viability, the expression of ATP-binding cassette sub-family G member 2 (ABCG2) and myeloid cell leukemia‑1 (Mcl-1), and activation of the PI3K-Akt pathway. 27221310 2016
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE Thus, these findings provided that in lung cancer cells, tumor suppressor miR-451 enhanced DPP sensitivity via regulation of Mcl-1 expression, which could be served as a novel therapeutic target for the treatment of chemotherapy resistant in lung cancer. 27686452 2016
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells. 25917317 2015
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE The TWEAK-Fn14 signaling axis enhances lung cancer cell survival and therapeutic resistance through Mcl-1, positioning both TWEAK-Fn14 and Mcl-1 as therapeutic opportunities in lung cancer. 24469836 2014
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 GeneticVariation disease BEFREE We had recently reported that regulatory variants of MCL1 contribute to enhanced promoter activity but reduced risk of lung cancer. 24852432 2014
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE API-1 rapidly and potently reduced the levels of Mcl-1 primarily in API-1-senstive lung cancer cell lines. 24261825 2013
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE Ouabain downregulates Mcl-1 and sensitizes lung cancer cells to TRAIL-induced apoptosis. 23174563 2013
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE We also demonstrated a positive correlation between MCL1 and Naa10p messenger RNA levels in both colon cancer and lung cancer tissues. 22496479 2012
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 GeneticVariation disease BEFREE Functional regulatory variants of MCL1 contribute to enhanced promoter activity and reduced risk of lung cancer in nonsmokers: implications for context-dependent phenotype of an antiapoptotic and antiproliferative gene in solid tumor. 21887682 2012
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE The most potent compound BI79D10 binds to Bcl-XL, Bcl-2, and Mcl-1 with IC50 values of 190, 360, and 520 nmol/L, respectively, and potently inhibits cell growth in the H460 human lung cancer cell line with an EC50 value of 680 nmol/L, expressing high levels of Bcl-2. 19372563 2009
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE MicroRNA 133B targets pro-survival molecules MCL-1 and BCL2L2 in lung cancer. 19654003 2009
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 Biomarker disease BEFREE Taken together, these results identify c-FLIP(L) and Mcl-1(L) as the major determinants of acquired TRAIL resistance and could be molecular targets for improving the therapeutic value of TRAIL against lung cancer. 18483303 2008
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung
0.100 AlteredExpression disease BEFREE Reduction in Mcl-1 levels can sensitize lung cancer cells to apoptosis induced by cytotoxic agents as well as by ionizing radiation. 15753661 2005